Charles Piller
Science Magazine
San Francisco Bay Area, CA, United States
Contact Charles
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Charles:
Second death linked to potential antibody treatment for Alzheimer’s disease
Woman’s brain hemorrhage while receiving Eisai’s widely heralded lecanemab heightens concerns overs its safety → Read More
Potential fabrication in research images threatens key theory of Alzheimer’s disease
A neuroscience sleuth challenges data showing one toxic form of amyloid protein is a cause of brain condition → Read More
Critics say a childhood asthma study unethically withheld care—and see a troubling trend
Science investigation reveals concerning details of vitamin D supplement trial that a whistleblower scientist calls “stunning and callous” → Read More
Biden Made a Promise to Scientists. He Can Still Keep It.
Researchers who receive federal help consistently fail to report their results to the public. The government should hold them accountable. → Read More
Disgraced researchers can still reap drug industry payouts
After disqualification for misconduct, some doctors gain vast sums for teaching or consulting → Read More
FDA and NIH let clinical trial sponsors keep results secret and break the law
Science investigation of ClinicalTrials.gov reveals that federal promises to enforce trial transparency have fizzled → Read More
Exclusive: FDA enforcement actions plummet under Trump
FDA actions that safeguard clinical trials, food and drug safety in steep decline, Science investigation reveals → Read More
Is FDA's revolving door open too wide?
The Food and Drug Administration (FDA) says its rules, along with federal laws, stop employees from improperly cashing in on their government service. But how adequate are those revolving door controls? Much like outside advisers (see main story, p. [16][1]), however, regular employees at the agency, headquartered in Silver Spring, Maryland, often reap later rewards—jobs or consulting work—from… → Read More
Hidden conflicts? Pharma payments to FDA advisers after drug approvals spark ethical concerns
Science investigation of journal disclosures and pharmaceutical funding records shows potential influence on physician gatekeepers → Read More
FDA’s revolving door: Companies often hire agency staffers who managed their successful drug reviews
FDA’s revolving door: Companies often hire agency staffers who managed their successful drug reviews By Charles PillerJul. 5, 2018 , 2:00 PM The Food and Drug Administration (FDA) says its rules, along with federal laws, stop employees from improperly cashing in on their government service. But how adequate are those revolving door controls? Science has found that much like outside advisers,… → Read More
Facing public pressure, research institutions step up clinical trial reporting
Clinical trial data is supposed to go into a federal database, but not everyone complies. STAT investigated the worst offenders in 2015. Here’s where they are now. → Read More
3 women in biotech finance to watch in 2018
Meet three women who have pushed to diversify the clubby venture capital world of Silicon Valley and are fighting to advance more women's careers in biotech and health care. → Read More
Picking locks, building robots: One woman’s rise in biotech
To rise to the stratosphere of the medical device industry in male-dominated Silicon Valley, Dr. Catherine Mohr followed her passion: making things. → Read More
What’s keeping Silicon Valley’s tech titans from radicalizing health care?
Silicon Valley has transformed commerce, technology, communications. Can it find a formula to disrupt and radicalize health care? → Read More
Why these powerful health care gurus left the East Coast for California
What happens when top doctors and scientists leave the power hubs of the East Coast for Silicon Valley? Here, their unvarnished views of California. → Read More
Q&A: An open-data evangelist preaches creative cooperation to speed drug development
SAN FRANCISCO — When Dr. Atul Butte thinks data, the word “big” can’t do it justice. He was honored by President Barack Obama’s administration as an “open science champion of… → Read More
California wildfires blanket region in smoky pollutants, raising health risks
The raging Northern California wildfires are fouling the air across the region, driving a significant uptick in hospitalizations. → Read More
An anarchist takes on Big Pharma — by promoting DIY prescription drugs
Michael Laufer published blueprints for a homemade "EpiPencil" and is now working on a kit to let patients make other medicines at home — patents be damned. → Read More
He puts science under a microscope: 'How do we know what's true?'
Dr. Steven Goodman has worked for decades to make science stronger and more reliable through “meta research” — research about research. → Read More
Mark Zuckerberg's big plan to cure disease has been a 'roller coaster'
Neurobiologist Cori Bargmann runs the Chan-Zuckerberg Initiative, which aims to get every disease that afflicts humanity under control. It's a tall order. → Read More